Every 8-K that Editas Medicine, Inc. (EDIT) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow EDIT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full EDIT filings page.
Editas Medicine, Inc. reported second quarter 2026 results, with collaboration and other research and development revenue of $11.9 million and a net loss of $18.2 million, or $0.15 per share, compared with a $53.2 million loss a year earlier. Cash and cash equivalents were $211.6 million as of June 30, 2026, and the company expects its cash runway to extend into the second half of 2028.
The company highlighted EDIT-401, its in vivo CRISPR program for Heterozygous Familial Hypercholesterolemia, stating it is on track to submit a Clinical Trial Notification in Australia this month and to initiate a Phase 1/2 trial, with a data update expected in the first quarter of 2027 and topline results in 2027. Preclinical non-human primate data showed roughly 90% or greater mean reductions in LDL-C, Lp(a), and ApoB after a single dose, with no adverse clinical observations at 1.5 mg/kg.
In May, Editas completed a public offering of common stock and warrants for aggregate gross proceeds of $125.0 million, with approximately $194.4 million in additional gross proceeds possible upon full warrant exercise. The company also announced that director Elliott Levy resigned and that Patrick Ellinor, M.D., Ph.D. was appointed as an independent class I director, with standard cash and equity compensation.
Editas Medicine held its 2026 annual stockholder meeting, where investors elected Bernadette Connaughton and Elliott Levy, M.D. as Class I directors to serve until the 2029 annual meeting. Connaughton received 28,660,181 votes for and 10,789,549 withheld, while Levy received 37,095,058 votes for and 2,354,672 withheld, in each case with 26,404,190 broker non-votes.
Stockholders also approved, on a non-binding advisory basis, the compensation of the company’s named executive officers, with 32,914,258 votes for, 6,322,885 against, 212,587 abstentions, and 26,404,190 broker non-votes. In addition, they ratified PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 64,686,839 votes for, 774,471 against, and 392,610 abstentions.
Editas Medicine entered into an underwriting agreement for an underwritten public offering of 55,555,556 shares of common stock and accompanying warrants, with each share-plus-warrant unit priced at $2.25. All securities are being sold by the company under an effective shelf registration.
The company expects net proceeds of about $117.0 million after underwriting discounts and expenses, excluding any warrant exercise proceeds. Management estimates that, combined with cash and cash equivalents as of March 31, 2026, this funding will support operations into the second half of 2028, though this outlook depends on assumptions that may change.
Editas Medicine, Inc. filed a current report describing a change to its equity distribution plans with TD Securities (USA) LLC, doing business as TD Cowen. The company has suspended and terminated the existing prospectus supplement for its “at-the-market” stock offering program under the Sales Agreement.
Editas states it will not sell additional common stock through this program unless and until a new prospectus or prospectus supplement is filed and, if needed, a new registration is declared effective by the SEC. The underlying Sales Agreement with TD Cowen remains in effect.
As of May 26, 2026, Editas had issued and sold 14,327,365 shares of common stock under this at-the-market program, generating aggregate gross sale proceeds of $43.9 million before sales commissions and offering expenses.
Editas Medicine reported new preclinical results and development plans for EDIT-401, its lead in vivo gene‑editing candidate for hyperlipidemia. In non-human primates, a single dose produced about 90% or greater average reductions in LDL-cholesterol, lipoprotein(a), and apolipoprotein B, key drivers of cardiovascular risk.
At a therapeutically relevant dose of 1.5 mg/kg, EDIT-401 was described as well-tolerated, with no adverse clinical observations, no notable treatment-related liver enzyme elevations, no liver histopathology findings, and a mean functional liver editing rate of 12.4%. Higher doses of 3 mg/kg and 6 mg/kg led to liver enzyme increases and adverse observations at the top dose.
The company plans to submit a Clinical Trial Notification in Australia by mid-2026, aiming to start a first-in-human trial in Heterozygous Familial Hypercholesterolemia later in 2026 and obtain early in vivo human proof-of-concept data by year-end 2026. The proposed Phase 1/2 design includes a Part 1 single ascending dose study in about 18 patients and a Part 2 randomized, placebo-controlled expansion in about 28 patients, with Part 1 topline results expected in 2027. Editas also received FDA pre-IND feedback it believes supports a future U.S. IND for EDIT-401.
Editas Medicine used this 8-K to share new preclinical results for its in vivo CRISPR candidate EDIT-401, being developed as a potential one-time treatment for hyperlipidemia. In non-human primates, a single dose across 1.5–3.0 mg/kg produced ≥90% mean LDL cholesterol reduction that appeared rapidly and remained durable for about six months.
The company reports this effect was achieved with only 10–40% functional editing of LDLR alleles and at least a six-fold mean increase in hepatic LDLR protein, with no adverse clinical observations at the therapeutically relevant 1.5 mg/kg dose. Mouse pharmacokinetic and pharmacodynamic data suggest dose adjustments may not be needed to achieve LDL-C lowering in heterozygous familial hypercholesterolemia patients, supporting continued advancement toward first-in-human studies.
Editas Medicine reported first quarter 2026 results and highlighted progress on its lead in vivo gene-editing program, EDIT-401, for hyperlipidemia and HeFH. Preclinical data showed more than 90% mean LDL-C reduction, and the company plans to start a first-in-human trial in 2026 with early proof-of-concept data expected by year-end and dose-finding topline data in 2027.
Cash and cash equivalents were $123.6 million as of March 31, 2026, which the company expects will fund operations into the third quarter of 2027. Net loss narrowed to $25.0 million, or $0.26 per share, compared with a net loss of $76.1 million, or $0.92 per share, a year earlier, driven by lower R&D and G&A expenses and the absence of prior-year restructuring and impairment charges.
Collaboration and other research and development revenues were $2.8 million, down from $4.7 million in the prior-year quarter, primarily because 2025 included remaining deferred revenue recognized when a collaboration ended. The U.S. Patent and Trademark Office also reaffirmed a prior Patent Trial and Appeal Board decision favoring the Broad Institute in a CRISPR/Cas9 interference involving patents exclusively licensed to Editas for use in human cells.
Editas Medicine, Inc. has replaced its long-time auditor, dismissing Ernst & Young LLP and appointing PricewaterhouseCoopers LLP as its new independent registered public accounting firm for the fiscal year ending December 31, 2026.
The Audit Committee made the change after soliciting proposals and conducting a formal review. Ernst & Young’s audit reports for 2024 and 2025 contained no adverse opinions or qualifications, and the company reports no disagreements or reportable events with Ernst & Young through April 1, 2026.
Editas Medicine announced that the U.S. Patent and Trademark Office has reaffirmed the Patent Trial and Appeal Board’s prior decision favoring the Broad Institute in a key CRISPR/Cas9 patent interference covering gene editing in human cells. This is the PTAB’s third favorable decision confirming Broad as first to invent CRISPR/Cas9 use in eukaryotic cells.
The CRISPR/Cas9 patents at issue are exclusively licensed to Editas for developing and commercializing CRISPR/Cas9-based medicines, underpinning its gene editing pipeline. Other in-licensed Broad, Harvard, MIT and collaborator patents, including CRISPR/Cas12a rights, are not involved in this interference and remain unaffected.
Management highlighted this outcome as reinforcing confidence in the company’s intellectual property as it advances in vivo gene editing programs, including EDIT-401, an experimental one-time therapy that has achieved greater than 90 percent mean LDL cholesterol reduction in non-human primates. CVC parties retain the right to appeal the decision to the Federal Circuit.
Editas Medicine reported sharply improved 2025 results while pivoting to its in vivo gene-editing program EDIT-401. Full-year net loss narrowed to $160.1M, or $1.80 per share, from $237.1M, helped by lower research and development and general and administrative expenses tied to discontinuing its former reni-cel program.
Collaboration and other R&D revenue grew to $40.5M in 2025, supported by milestone and deferred revenue recognition. Cash, cash equivalents, and marketable securities were $146.6M as of December 31, 2025, and the company projects cash runway into the third quarter of 2027.
Lead candidate EDIT-401 reduced mean LDL cholesterol by more than 90% in non-human primates and is expected to have an IND/CTA submission by mid-2026, with a first-in-human HeFH trial planned later in 2026 and early human proof-of-concept data targeted by year-end 2026.
Editas Medicine reported that it furnished a press release announcing financial results for the fiscal quarter ended September 30, 2025, along with other business highlights.
The press release was provided as Exhibit 99.1 and designated as furnished, not filed. The company’s common stock trades on Nasdaq under the symbol EDIT.
Editas Medicine, Inc. filed a report describing new preclinical data for EDIT-401, an experimental one-time gene-editing therapy designed to significantly reduce LDL-cholesterol by increasing LDL receptor levels. At a major gene and cell therapy congress, the company reported that in non-human primates a single dose of EDIT-401 led to LDL-C reductions equal to or exceeding 90% within 48 hours. Similar LDL-C reductions of at least 90% were also seen in mice with high baseline LDL-C and reduced LDL receptor function, with effects maintained over a three-month study. The therapy uses a CRISPR/Cas9 nuclease with dual guide RNAs delivered via lipid nanoparticles to disrupt negative regulatory elements in the 3’ UTR, which Editas says increased LDL receptor protein in primate liver by at least six-fold while requiring only moderate functional editing of LDLR alleles.
Editas Medicine used this report to highlight a new in vivo gene-editing candidate, EDIT-401, designed to treat hyperlipidemia by editing the LDLR gene to increase LDL receptor protein and lower LDL cholesterol. In non-human primates, a single dose produced about a 90 percent mean reduction in LDL-C across four dose levels and at least a six-fold mean increase in liver LDLR protein, with no adverse effects reported and transient liver enzyme elevations resolving within one week.
The company plans to prioritize EDIT-401, aiming to submit an IND or CTA by mid-2026 and to achieve in vivo human proof-of-concept data by the end of 2026, while continuing earlier work on hematopoietic stem cell and other cell-type programs. It reaffirmed that existing cash, cash equivalents, marketable securities, and retained portions of payments from its Vertex license are expected to fund operations and capital needs into the second quarter of 2027.
Editas Medicine announced that it has furnished a press release reporting its financial results for the fiscal quarter ended June 30, 2025 and other business highlights. The press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is expressly furnished, not filed, so the numerical results and business detail are contained in that exhibit rather than in the body of the filing.